Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Revvity (RVTY) reported revenue of $729.37 million for the quarter ended December 2024, reflecting a year-over-year increase of 4.8% [1] - The company's EPS was $1.42, up from $1.25 in the same quarter last year, surpassing the consensus estimate of $1.36 by 4.41% [1] - The revenue fell slightly short of the Zacks Consensus Estimate of $730.06 million, resulting in a surprise of -0.10% [1] Financial Performance Metrics - Organic revenue growth in Life Sciences was 5%, exceeding the average estimate of 2.7% from three analysts [4] - Total organic revenue growth was reported at 6%, compared to the average estimate of 4.1% [4] - Organic revenue growth in Diagnostics was 6%, surpassing the average estimate of 5.5% [4] Sales Performance - Net Sales in Life Sciences reached $336.34 million, slightly below the average estimate of $344.79 million, but still showing a year-over-year increase of 5.2% [4] - Net Sales in Diagnostics amounted to $393.24 million, exceeding the average estimate of $385.63 million, with a year-over-year growth of 4.5% [4] Stock Performance - Revvity's shares have returned +13.3% over the past month, outperforming the Zacks S&P 500 composite's +2.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]